The CDKN2A acts as a cyclin-dependent kinase inbibitor, inbibiting the binding of the CDK4 selleck chemicals protein to cylclin D1 and thus preventing phosphorylation of the Rb protein and arresting the cell cycle in the G1phase [18, 19]. Cyclin D1 overexpression, CDKN2A loss, and pRb inactivation play a key role in glioma tumorigenesis [20–22]. The results indicated that overexpression CDKN2A has the potential to be developed into a future

treatment for glioma patients. Conclusions Our study suggests that CDKN2A as a malignant gliomas suppressor gene, appears to be useful for predicting behaviour of high-grade malignant gliomas. CDKN2A-Cyclin-Rb pathway plays a key role on malignant gliomas formation and that therapeutic targeting of this pathway may be useful in malignant gliomas treatment. References 1. Ohgaki H, Kleihues P: Epidemiology OSI-906 purchase and etiology of gliomas. Acta Neuropathol 2005, 109:93–108.PubMedCrossRef 2. Rasheed BK, Wiltshire RN, Bigner SH, Bigner DD: Molecular pathogenesis of malignant gliomas. Curr Opin Oncol 1999, 11:162–167.PubMedCrossRef 3. Bigner SH, Mark J, Burger PC, Mahaley MS Jr, Bullard DE, Muhlbaier LH, Bigner

DD: Specific chromosomal abnormalities in malignant human gliomas. Cancer Res 1988, 48:405–411.PubMed 4. Bigner SH, Friedman HS, Biegel JA, Wikstrand CJ, Mark J, Gebhardt R, Eng LF, Bigner DD: Specific chromosomal abnormalities characterize four established cell lines derived from malignant human gliomas. Acta Neuropathol 1986, 72:86–97.PubMedCrossRef Protein tyrosine phosphatase 5. Bigner SH, Wong AJ, Mark J, Muhlbaier LH, Kinzler KW, Vogelstein B, Bigner DD: Relationship between gene amplification and chromosomal deviations in malignant selleckchem human gliomas. Cancer Genet Cytogenet

1987, 29:165–170.PubMedCrossRef 6. Comprehensive genomic characterization defines human glioblastoma genes and core pathways Nature 2008, 455:1061–1068. 7. Blumenthal DT, Cannon-Albright LA: Familiality in brain tumors. Neurology 2008, 71:1015–1020.PubMedCrossRef 8. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, et al.: IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009, 360:765–773.PubMedCrossRef 9. Liggett WH Jr, Sidransky D: Role of the p16 tumor suppressor gene in cancer. J Clin Oncol 1998, 16:1197–1206.PubMed 10. Sekine C, Sugihara T, Miyake S, Hirai H, Yoshida M, Miyasaka N, Kohsaka H: Successful treatment of animal models of rheumatoid arthritis with small-molecule cyclin-dependent kinase inhibitors. J Immunol 2008, 180:1954–1961.PubMed 11. Ruef J, Meshel AS, Hu Z, Horaist C, Ballinger CA, Thompson LJ, Subbarao VD, Dumont JA, Patterson C: Flavopiridol inhibits smooth muscle cell proliferation in vitro and neointimal formation In vivo after carotid injury in the rat. Circulation 1999, 100:659–665.PubMed 12. Shete S, Hosking FJ, Robertson LB, Dobbins SE, Sanson M, Malmer B, Simon M, Marie Y, Boisselier B, Delattre JY, et al.